治疗性压力触发瘤STAT1乙化,以解除免疫治疗的作用
Po-Hsien Chiu1, Kuan-Chen Lai2, Hung-Ling Wang3
1Program in Molecular Medicine, National Yang Ming Chiao Tung University and Academia Sinica, Taipei 112304, Taiwan.
Cell reports. Medicine
|November 8, 2025
概括
之前的 cetuximab 治疗可能会导致头癌对免疫治疗产生抵抗力. STAT1乙化是一种新奇的修饰,预测免疫疗法反应,并可能指导治疗决策.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 顺序性癌症治疗的有效性往往受到先前治疗的限制.
- 塞图西马布对随后的免疫治疗,特别是免疫检查点阻塞 (ICB) 的影响,在头部和部状细胞癌 (HNSCC) 中尚不清楚.
研究的目的:
- 调查长时间暴露于塞图西马布如何影响HNSCC中瘤对ICB的反应.
- 阐明治疗诱导的免疫抵抗背后的分子机制.
- 为了确定潜在的生物标志物来预测 cetuximab 治疗后的 ICB 疗效.
主要方法:
- 对患者数据的多中心分析,将 cetuximab 治疗持续时间与 ICB 反应和存活率相关联.
- 涉及瘤样本分子分析的机制研究,以确定关键蛋白质修饰.
- 研究STAT1乙化,酸化和降解途径,以应对治疗性压力.
主要成果:
- 在HNSCC中延长塞图西马布治疗与ICB反应减少和生存率降低相关.
- 慢性治疗性压力诱导瘤内从炎症过渡到免疫抵抗.
- 确定了STAT1 lysine 637乙化作为一种分子开关,损害了STAT1功能,并破坏了瘤对干扰素- (IFN-γ) 的反应.
- 在预处理样本中的STAT1乙化作为ICB疗效的预测生物标志物.
结论:
- 长时间的塞图西马布治疗可以诱导HNSCC中瘤对ICB的内在抵抗力.
- STAT1乙化是这种抗性的关键媒介,作为分子开关.
- STAT1乙化是一种有前途的预测生物标志物,用于指导先前用 cetuximab 治疗的 HNSCC 患者的免疫疗法决策.
更多相关视频
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
1.4K
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
1.7K
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Psychoneuroimmunology: Diabetes and Cancer
420
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
420
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
